Insmed to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) has announced the release date for its first quarter 2021 financial results as May 6, 2021. A conference call for investors will take place at 8:30 a.m. ET on the same day, where management will discuss the financial outcomes and provide a business update. Interested parties can join the call through a provided dial-in number or via a live webcast on the company's website. The company focuses on transforming the lives of patients with serious and rare diseases, having a first-in-disease therapy approved in the US, Europe, and Japan.

Positive

• Scheduled conference call for financial results indicates transparent communication with investors.
• Focus on serious and rare diseases aligns with high unmet medical needs, suggesting potential for significant market opportunities.

Negative

• None.

BRIDGEWATER, N.J., April 22, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, May 6, 2021 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (833) 340-0284 (domestic) or (236) 712-2425 (international) and referencing conference ID number 2257423. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately two hours after its completion through June 5, 2021 by dialing (800) 585-8367 (domestic) or (416) 621-4642 (international) and referencing conference ID number 2257423. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-first-quarter-2021-financial-results-conference-call-on-thursday-may-6-2021-301274196.html

SOURCE Insmed Incorporated

FAQ

When will Insmed release its first quarter 2021 financial results?

Insmed will release its first quarter 2021 financial results on May 6, 2021.

What time is the Insmed conference call regarding financial results?

The conference call will take place at 8:30 a.m. ET on May 6, 2021.

How can I participate in Insmed's financial results conference call?

Participants can join by dialing (833) 340-0284 (domestic) or (236) 712-2425 (international) and referencing conference ID 2257423, or by accessing the live webcast on Insmed's website.

What is Insmed's focus in the biopharmaceutical sector?

Insmed is focused on developing therapies for patients with serious and rare diseases, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders.